NovoCure (NVCR) Gains from Sales and Divestitures (2018 - 2019)

NovoCure's (NVCR) quarterly Gains from Sales and Divestitures came in at $723554.0 in Q2 2019, up 31.46% year-on-year from $550418.0 in Q2 2018, and up 84.96% quarter-over-quarter from $391191.0 in Q1 2019.

NovoCure (NVCR) Gains from Sales and Divestitures (2018 - 2019) Analysis & Trends

NovoCure has disclosed Gains from Sales and Divestitures across 2 years of filings, most recently posting $723554.0 for Q2 2019.

  • Gains from Sales and Divestitures for Q2 2019 came in at $723554.0, up 31.46% year-over-year; the trailing twelve-month figure through Jun 2019 was $723554.0 (up 31.46% YoY), and the FY2018 annual result was $556563.0, changed N/A from the prior year.
  • Gains from Sales and Divestitures came in at $723554.0 for Q2 2019 at NovoCure, up from $391191.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $723554.0 in Q2 2019 to a low of $256578.0 in Q1 2018.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn
10 NovoCure 1.63 Bn 1.20 Bn 135.13 Mn

Historic Data

Download Data
DateValue
Jun 30, 2019 723,554.00
Jun 30, 2019 723,554.00
Mar 31, 2019 391,191.00
Mar 31, 2019 391,191.00
Dec 31, 2018 556,563.00
Dec 31, 2018 556,563.00
Sep 30, 2018 550,418.00
Sep 30, 2018 550,418.00
Jun 30, 2018 550,418.00
Jun 30, 2018 550,418.00
Mar 31, 2018 256,578.00
Mar 31, 2018 256,578.00